The transcript to the recent conference call (3/19/14) available on Seeking Alpha. Follow the link below.
http://seekingalpha.com/article/2098253-international-stem-cells-management-discusses-q4-2013-results-earnings-call-transcript?page=1
Thursday, March 20, 2014
International Stem Cell Corporation Announces 2013 Fourth Quarter and Year-end Results
CARLSBAD, CA - (Marketwired) – March 18, 2014, International
Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com)
(“ISCO” or “the Company”), a California-based biotechnology company developing
novel stem cell-based therapies and biomedical products, today provided a
business update and announced fourth quarter and year-end financial results for
the year ended December 31, 2013.
Parkinson’s disease program
highlights:
The
company continues to execute on its plan to develop human parthenogenetic
neural stem cells (hPNSC) as a clinical product candidate for the treatment of
Parkinson’s disease (PD). To this end the Company has:
- Published its breakthrough method of manufacturing hPNSC in Scientific Reports, a primary research publication from the publishers of Nature.
- Reported positive results demonstrating the safety and efficacy of hPNSC in both rodent and non-human primate models of PD, presenting the results at the American Academy of Neurology 65th Annual Meeting in San Diego, CA, the American Society of Gene and Cell Therapy meeting in Salt Lake City, UT and the American Neurological Association 2013 Annual Meeting in New Orleans, LA
- Began the IND-enabling non-human primate pharmacology and toxicology GLP study under the supervision of Yale School of Medicine Professor, D. Eugene Redmond Jr. MD.
- Engaged Duke University to conduct the Phase I clinical trial of the hPNSC for the treatment of PD. Prof. Mark Stacy, M.D., Vice Dean for Clinical Research, Neurology at Duke University School of Medicine, will be the principal investigator.
- Most recently in February 2014 the Company held a pre-IND meeting with the FDA and subsequently announced that it will be working to complete the FDA required pharmacology and safety studies by the end of 2014, and file the IND shortly thereafter. In 2014 ISCO will also be working toward bringing forward additional indications for hPNSC.
Liver program highlights
- Demonstrated that the hepatocyte-like cells derived from ISCO’s parthenogenetic stem cell platform engraft in the liver of Gunn rats, a well known model of Crigler-Najjar Syndrome, a rare inherited disorder of the liver, and behave in a similar manner to primary human hepatocytes.
- The results of this study were presented at the American Association for the Study of Liver Disease at the 64th Annual Liver Meeting in Washington, D.C. and were awarded the Presidential Poster of Distinction.
Other
R&D activities
- Announced a significant advancement in human induced pluripotent stem cells (iPS) derivation using a novel protein-based reprogramming method at the American Society of Gene and Cell Therapy meeting in Salt Lake City, UT.
FY 2013 Financial
highlights:
- $6.15 million in revenue for the year ended December 31, 2013, an increase of 35% compared to 2012. Lifeline Skin Care sales up 47% and Lifeline Cell Technology sales up 24%. Gross margin improved to 73% in 2013 from 72% in 2012.
- Subsidiaries generated operating income in 2013 of $0.65 million (cosmeceutical $0.29 million, biomedical $0.36 million), compared to operating loss in 2012.
- Average net cash used in operating activities of $0.47 million per month for the twelve months ending December 31, 2013. The company ended 2013 with cash of $2.24 million.
- Net cash provided by financing activities was $8.12 million for the year ended December 31, 2013, compared to $6.79 million in 2012.
“In 2013 ISCO
made important progress in Research and Development, primarily in the
Parkinson’s disease program, achieving a number of milestones that move us
closer to the clinic. In 2014 we will be
endeavoring to complete our IND-enabling studies in order to file our first IND
for our new experimental treatment of PD,” stated Dr. Andrey Semechkin, ISCO’s
CEO and Co-chairman. “At the same time
we continue to execute on our business plan, growing revenues in our commercial
subsidiaries while maintaining costs,” Dr. Semechkin concluded.
ISCO to host conference
call and webcast:
Date:
Wednesday, March 19, 2014
Time:
11:00 a.m. ET
Toll-free
(US only): 1-877-941-1427
International:
1-480-629-9664
Conference ID: 4673819
Please dial in at least 10 minutes before
the call to ensure timely participation.
A playback of the call will be available
from 03/19/14 at 2:00 pm Eastern Time to 04/02/14 at 11:59 pm Eastern Time.
Teleconference Replay Details:
Dial in:
1-858-384-5517
Conference ID: 4673819
About
International Stem Cell Corporation
International Stem Cell Corporation is focused on the
therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development
and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis,
results in the creation of pluripotent human stem cells from unfertilized
oocytes (eggs). hpSCs avoid ethical
issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first
parthenogenetic, homozygous stem cell line that can be a source of therapeutic
cells for hundreds of millions of individuals of differing genders, ages and
racial background with minimal immune rejection after transplantation. hpSCs
offer the potential to create the first true stem cell bank, UniStemCell™. ISCO
also produces and markets specialized cells and growth media for therapeutic
research worldwide through its subsidiary Lifeline Cell Technology
(www.lifelinecelltech.com), and stem cell-based skin care products through its
subsidiary Lifeline Skin Care (www.lifelineskincare.com). More information is
available at www.internationalstemcell.com.
To subscribe to receive ongoing corporate
communications, please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0
To like our Facebook page or follow us on Twitter for
company updates and industry related news, visit: www.facebook.com/InternationalStemCellCorporation
and www.twitter.com/intlstemcell
Safe
harbor statement
Statements pertaining to anticipated developments,
expected pre-clinical studies and results, progress of research and
development, potential sales growth, and
other opportunities for the company and its subsidiaries, along with other
statements about the future expectations, beliefs, goals, plans, or prospects
expressed by management constitute forward-looking statements. Any statements
that are not historical fact (including, but not limited to statements that
contain words such as "will," "believes,"
"plans," "anticipates," "expects,"
"estimates,") should also be considered to be forward-looking
statements. Forward-looking statements involve risks and uncertainties,
including, without limitation, risks inherent in the development and/or commercialization
of potential products, regulatory approvals, need and ability to obtain future
capital, application of capital resources among competing uses, and maintenance
of intellectual property rights. Actual results may differ materially from the
results anticipated in these forward-looking statements and as such should be
evaluated together with the many uncertainties that affect the company's
business, particularly those mentioned in the cautionary statements found in
the company's Securities and Exchange Commission filings. The company disclaims
any intent or obligation to update forward-looking statements.
International Stem Cell Corporation and Subsidiaries
Consolidated Balance
Sheets
(in thousands, except
share data)
|
|
|
|
|
|
December 31,
2013 |
December 31,
2012 |
|
|
|
|
|
Assets
|
|
|
|
Cash and cash
equivalents.........................................................................................................................
|
$ 2,243
|
$ 654
|
|
Accounts receivable, net of allowance for doubtful
accounts of $19 and $4 at December 31, 2013 and 2012, respectively.................................................................................................................
|
306
|
273
|
|
Inventory, net...............................................................................................................................................
|
1,369
|
1,199
|
|
Prepaid expenses and other current assets..............................................................................................
|
658
|
456
|
|
Restricted cash..............................................................................................................................................
|
50
|
—
|
|
|
|
|
|
Total current assets...........................................................................................................................
|
4,626
|
2,582
|
|
Property and equipment, net......................................................................................................................
|
830
|
1,134
|
|
Intangible assets, net...................................................................................................................................
|
2,250
|
1,634
|
|
Deposits and other assets............................................................................................................................
|
33
|
20
|
|
|
|
|
|
Total assets.........................................................................................................................................
|
$ 7,739
|
$ 5,370
|
|
|
|
|
|
Liabilities, Redeemable Preferred Stock and
Stockholders’ Equity (Deficit)
|
|
|
|
Accounts payable........................................................................................................................................
|
$ 532
|
$ 969
|
|
Accrued liabilities.........................................................................................................................................
|
1,290
|
730
|
|
Deferred revenue..........................................................................................................................................
|
3
|
233
|
|
Related party payable.................................................................................................................................
|
21
|
5
|
|
Advances.......................................................................................................................................................
|
250
|
250
|
|
Fair value of warrant liability.....................................................................................................................
|
4,925
|
—
|
|
|
|
|
|
Total current liabilities......................................................................................................................
|
7,021
|
2,187
|
|
|
|
|
|
Convertible Redeemable Series G Preferred stock,
$0.001 par value, 5,000,000 shares authorized, issued and outstanding at December 31,
2013 and 2012, with liquidation preference of $5,000 at December 31,
2013 and 2012.........................................................................................................................
|
4,941
|
4,941
|
|
|
|
|
|
Commitments and contingencies
|
|
|
|
|
|
|
|
Stockholders’ Equity (Deficit)
|
|
|
|
Series D Preferred stock, $0.001 par value, 50
shares authorized, 43 issued and outstanding at December 31, 2013
and 2012, with liquidation preference of $4,320 at December 31, 2013 and
2012.....................................................................................................................................................................
|
—
|
—
|
|
Series B Preferred stock, $0.001 par value,
5,000,000 shares authorized, 300,000 issued and outstanding at
December 31, 2013 and 2012, liquidation preferences of $403 and $385 at
December 31, 2013 and 2012, respectively.................................................................................................
|
—
|
—
|
|
Series C Preferred stock, $0.001 par value, 0 and
3,000,000 shares authorized, 0 and 2,000,000 issued and outstanding at December 31,
2013 and 2012, respectively, with liquidation preferences of $0 and $2,507 at
December 31, 2013 and 2012, respectively............................................................
|
—
|
2
|
|
Common stock, $0.001 par value, 300,000,000 shares
authorized, 151,175,053 and 87,388,815 issued and outstanding at December 31,
2013 and 2012, respectively..................................................
|
151
|
87
|
|
Additional paid-in capital......................................................................................................................................
|
77,897
|
69,945
|
|
Accumulated deficit....................................................................................................................................
|
(82,271 )
|
(71,792 )
|
|
|
|
|
|
Total stockholders’ deficit..........................................................................................................................
|
(4,223 )
|
(1,758 )
|
|
|
|
|
|
Total liabilities, redeemable preferred stock and
stockholders’ equity (deficit)...............................
|
$ 7,739
|
$ 5,370
|
|
|
|
|
International Stem Cell Corporation and Subsidiaries
Consolidated
Statements of Operations
(in thousands, except
per share data)
|
|
|
|
|
|
Year Ended December 31,
|
|
|
|
2013
|
2012
|
|
Revenues
|
|
|
|
Product sales.............................................................................................................................
|
$ 6,147
|
$ 4,567
|
|
|
|
|
|
Total revenue.................................................................................................................
|
6,147
|
4,567
|
|
|
|
|
|
Expenses |
|
|
|
Cost of sales..............................................................................................................................
|
1,643
|
1,272
|
|
Research and development....................................................................................................
|
3,560
|
3,599
|
|
Selling and marketing..............................................................................................................
|
2,457
|
2,065
|
|
General and administrative....................................................................................................
|
6,033
|
7,446
|
|
|
|
|
|
Total expenses...............................................................................................................
|
13,693
|
14,382
|
|
|
|
|
|
Loss from operating activities.......................................................................................................
|
(7,546 )
|
(9,815 )
|
|
|
|
|
|
Other income (expense)
|
|
|
|
Fair value of warrant liability in excess of
proceeds..........................................................
|
(1,390 )
|
—
|
|
Financing transaction costs....................................................................................................
|
(738 )
|
—
|
|
Change in fair value of warrant liability..............................................................................
|
(754 )
|
38
|
|
Miscellaneous expense............................................................................................................
|
(74 )
|
(61 )
|
|
Interest expense........................................................................................................................
|
(3 )
|
(2 )
|
|
Sublease income.......................................................................................................................
|
26
|
7
|
|
|
|
|
|
Total other (expense), net............................................................................................
|
(2,933 )
|
(18 )
|
|
|
|
|
|
Loss before income taxes................................................................................................................
|
(10,479 )
|
(9,833 )
|
|
Provision for income taxes................................................................................................................
|
—
|
—
|
|
|
|
|
|
Net loss.................................................................................................................
|
$ (10,479 )
|
$ (9,833 )
|
|
|
|
|
|
Deemed dividend on preferred stock..............................................................................................
|
$ —
|
$ (1,375 )
|
|
Dividends on preferred stock............................................................................................................
|
$ —
|
$ (129 )
|
|
|
|
|
|
Net loss attributable to common stockholders..............................................................................
|
$ (10,479 )
|
$ (11,337 )
|
|
|
|
|
|
Net loss per common share-basic and diluted............................................................................
|
$ (0.09 )
|
$ (0.13 )
|
|
|
|
|
|
Weighted average shares-basic and diluted...............................................................................
|
123,088
|
85,936
|
|
|
|
|
Contacts:
International
Stem Cell Corporation
Dr.
Simon Craw, Executive Vice President of Business Development
Phone:
760-940-6383
Subscribe to:
Posts (Atom)